keyword
MENU ▼
Read by QxMD icon Read
search

Degludec

keyword
https://www.readbyqxmd.com/read/28077204/review-of-the-next-generation-of-long-acting-basal-insulins-insulin-degludec-and-insulin-glargine
#1
Matthew Stailey, Susan E Conway
Older adults are at an increased risk of developing type 2 diabetes mellitus (T2DM). Although oral agents (i.e., metformin) are the preferred first-line therapy, older adults often eventually require the addition of insulin to control their blood glucose. Long-acting insulin analogues are the preferred insulin products for older adults with T2DM. Insulin degludec and insulin glargine U-300 are both new generation long-acting insulins. When compared with the standard of care, long-acting insulin product insulin glargine U-100, insulin degludec, and insulin glargine U-300 had similar glucose-lowering effects, longer half-lives and durations of action, and a more even distribution over a 24-hour period...
January 1, 2017: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/28063135/cost-effectiveness-of-insulin-degludec-plus-liraglutide-ideglira-in-a-fixed-combination-for-uncontrolled-type-2-diabetes-mellitus-in-sweden
#2
Åsa Ericsson, Adam Lundqvist
BACKGROUND: Patients with uncontrolled type 2 diabetes mellitus (T2DM) are a priority group for intensified therapy without weight gain and with low risk of hypoglycaemia. OBJECTIVE: This study evaluates the cost effectiveness of insulin degludec plus liraglutide (IDegLira, Xultophy(®)) compared with six potential intensification treatment options for patients with T2DM that is uncontrolled with basal insulin. METHODS: The Swedish Institute for Health Economics (IHE) Cohort Model of Type 2 Diabetes was used with Swedish input data, a 40-year time frame and a societal perspective...
January 6, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28035840/cost-effectiveness-of-switching-to-insulin-degludec-from-other-basal-insulins-evidence-from-swedish-real-world-data
#3
Lena Landstedt-Hallin, Jens Gundgaard, Åsa Ericsson, Susanne Ellfors-Zetterlund
OBJECTIVES: Health economic analysis from a health care and societal point of view was conducted to assess cost-effectiveness of insulin degludec (IDeg) after switching from other basal insulins in people with type 1 diabetes. MATERIAL AND METHODS: This was a prospective, open-label, single arm, observational follow-up from August 2013-October 2015 of 476 consecutive patients at Danderyd Hospital [Stockholm, Sweden] who switched to IDeg from other basal insulins (99% basal insulin analogs)...
December 30, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27973209/cost-effectiveness-of-insulin-degludec-treatment-in-patients-with-type1-and-type-2-diabetes-mellitus-a-systematic-review
#4
X Yue, H J Guan, J Wu, X Bai
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972251/a-comparison-of-insulin-degludec-clinical-evaluations-and-recommendations-between-an-independent-hta-and-national-hta-bodies
#5
E M Oehrlein, M L Hanna, L Bjoernebo, E M Perfetto
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972238/insulin-degludec-in-clinical-practice-a-systematic-review-of-japanese-real-world-data
#6
K Kaku, M L Wolden, J Hyllested-Winge, E Nørtoft
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972201/cost-utility-analysis-of-insulin-degludec-vs-insulin-glargine-u100-treatment-in-patients-with-diabetes-mellitus-type-1-and-2-in-serbia
#7
M Culic, M Russel-Szymczyk, B Chubb, C Tikkanen
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972194/cost-effectiveness-analysis-of-insulin-degludec-compared-with-insulin-glargine-in-the-management-of-type-1-and-type-2-diabetes-mellitus-from-the-spanish-national-health-system-perspective
#8
A Ramirez de Arellano, P Mezquita, J Darba
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972193/annual-cost-and-effects-of-switching-to-insulin-degludec-from-other-basal-insulins-evidence-from-swedish-real-world-data
#9
J Gundgaard, L Landstedt-Hallin, Å Ericsson, S Ellfors-Zetterlund
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972189/cost-effectiveness-of-insulin-degludec-insulin-aspart-idegasp-compared-with-biphasic-insulin-aspart-biasp-30-in-patients-with-type-2-diabetes-mellitus-from-a-mexican-healthcare-perspective
#10
V Sánchez-Pedraza, B B Hansen, J Gundgaard, J García Uranga Romano, M Evans
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972154/real-life-data-demonstrate-significant-reductions-in-hba1c-in-t2dm-patients-switching-from-other-insulins-to-insulin-degludec
#11
C Melzer Cohen, B L Thorsted, M L Wolden, G Chodick, A Karasik
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27943107/the-efficacy-of-ideglira-insulin-degludec-liraglutide-combination-in-adults-with-type-2-diabetes-inadequately-controlled-with-a-glp-1-receptor-agonist-and-oral-therapy-dual-iii-randomized-clinical-trial
#12
Sultan Linjawi, Bruce W Bode, Louis B Chaykin, Jean-Pierre Courrèges, Yehuda Handelsman, Lucine M Lehmann, Abhishek Mishra, Richard W Simpson
INTRODUCTION: The progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), with the majority of patients eventually requiring insulin therapy. Therefore, this trial aimed to investigate the efficacy of IDegLira (combination of insulin degludec and liraglutide) in controlling glycemia in adults with type 2 diabetes who were inadequately controlled on a GLP-1RA and OADs...
December 10, 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27921428/-promising-molecules-for-treatment-of-hyperglycemia-in-patients-with-type-2-diabetes
#13
Milan Kvapil
New antidiabetic drugs are being developed today that expand the range of pharmacological intervention, in particular for patients with type 2 diabetes (imeglimin, semaglutide, dulaglutide, FGF 21 analogue). At the same time innovations take place that "better" the well-proven molecules, they offer new application forms we have no experience of diabetology (osmotic pump for exenatide, faster acting insulin aspart). New properties are brought by just the change of concentration (insulin glargine in a concentration of 300 U/ml), unexpected positive results are also brought by new fixed-ratio combinations of antidiabetics (fixed-ratio combination of insulin degludec and liraglutide, fixed-ratio combination of insulin glargine and lixisenatide)...
2016: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/27861265/drug-updates-and-approvals-2016-in-review
#14
Lindsy Meadowcraft, Geoffrey Mospan, Taylor Morrisette, Katie Smart, Melissa Janis
In 2016, the FDA approved several new drugs for use in primary care. These drugs include amphetamine extended-release orally disintegrating tablets (Adzenys XR-ODT), elbasvir and grazoprevir (Zepatier), emtricitabine and tenofovir alafenamide (Descovy), glycopyrrolate and formoterol (Bevespi Aerosphere), insulin degludec injection (Tresiba), and ixekizumab (Taltz).
December 16, 2016: Nurse Practitioner
https://www.readbyqxmd.com/read/27853981/intensification-of-idegasp-twice-daily-adding-insulin-aspart-vs-switching-to-basal-bolus-exploratory-randomized-trial-in-type-2-diabetes
#15
Wan Mohamaed Wan Bebakar, Louis Chaykin, Malene Lundgren Hersløv, Søren Rasmussen
INTRODUCTION: In a preceding trial comparing two different titration schemes, insulin degludec/insulin aspart (IDegAsp) showed good efficacy for achieving HbA1c <7% when administered twice daily (BID) in patients with uncontrolled type 2 diabetes (T2D). However, poor glycemic control persisted in a minority of patients. The current exploratory trial investigated the efficacy and safety of intensifying IDegAsp BID treatment in these patients by either adding a once-daily (OD) bolus injection of insulin aspart (IAsp) or by switching to a basal-bolus regimen of insulin degludec (IDeg) plus IAsp taken three times a day (TID)...
November 16, 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27846338/an-evolutionary-perspective-on-basal-insulin-in-diabetes-treatment-innovations-in-insulin-insulin-degludec-u-100-and-u-200
#16
Athena Philis-Tsimikas
Insulin degludec (IDeg) is a long-acting basal human insulin analog produced using recombinant DNA technology. The insulin structure is modified at the B30 position to allow a di-hexamer conformation in the presence of phenol and zinc.
October 2016: Journal of Family Practice
https://www.readbyqxmd.com/read/27836130/insulin-degludec-lixisenatide-and-patiromer-sorbitex-calcium
#17
Daniel A Hussar, Melissa N White
No abstract text is available yet for this article.
November 2016: Journal of the American Pharmacists Association: JAPhA
https://www.readbyqxmd.com/read/27799746/insulin-glargine-300-u-ml-in-the-management-of-diabetes-clinical-utility-and-patient-perspectives
#18
REVIEW
Bastiaan E de Galan
There is ongoing interest in optimizing basal insulin treatment by developing insulins with a flat pharmacological profile, a long duration of action (typically beyond 24 hours) and minimum day-to-day variation. Glargine-300 is a modified form of the long-acting insulin analog glargine in that it has been concentrated at 300 units/mL rather than the conventional 100 units/mL. Glargine-300 has a longer duration of action and a flatter pharmacological profile than original glargine-100. This property allows for more flexibility around the timing of administration, when injected once per day...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27764979/budget-impact-of-treating-commercially-insured-type-1-and-type-2-diabetes-patients-in-the-united-states-with-insulin-degludec-compared-to-insulin-glargine
#19
James Weatherall, Lisa Bloudek, Sarah Buchs
OBJECTIVE: To quantify the annual budget impact if all US commercially insured type 1 diabetes mellitus patients on basal-bolus therapy (T1DMBBT), type 2 diabetes mellitus patients on basal-oral therapy (T2DMBOT), and type 2 diabetes mellitus patients on basal-bolus therapy (T2DMBBT) switched from insulin glargine (IGlar) to insulin degludec (IDeg). METHODS: A short-term (1 year) budget impact model was developed to evaluate the costs of IDeg vs. IGlar in three treatment groups (T1DMBBT, insulin-naïve T2DMBOT, and T2DMBBT) through a simulation for a potential US health plan population of 35 million...
February 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27760129/efficacy-and-safety-of-once-daily-insulin-degludec-insulin-aspart-versus-insulin-glargine-u100-for-52-weeks-in-insulin-na%C3%A3-ve-patients-with-type-2-diabetes-a-randomized-controlled-trial
#20
Ajay Kumar, Edward Franek, Jonathan Wise, Marcus Niemeyer, Henriette Mersebach, Rafael Simó
PURPOSE: The efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD over 52 weeks in insulin-naïve adults with type 2 diabetes mellitus (T2DM) was investigated. METHODS: In this open-label, parallel-group treat-to-target trial, participants were randomized (1:1) to receive IDegAsp OD (breakfast, n = 266) or IGlar OD (as per label, n = 264). Participants then entered a 26-week extension phase (IDegAsp OD, n = 192; IGlar OD, n = 221)...
2016: PloS One
keyword
keyword
10126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"